FibroTrap is a fibrinogen-based technology allowing separation and concentration of target molecules from liquid samples within a sample-collection tube.
It is applicable to a variety of matrices (blood, urine, swabs, food, etc.) to isolate targets (bacteria, viruses, tumor cells, etc.) so could provide a 'breakthrough' in sample processing applied to clinical diagnostics and the food industry, said the firms.
They added the technology simplifies the sample processing workflow, improves sensitivity and shortens the time taken from sample collection to delivery of results.
Heiner Dreismann, chairman of the board, said the agreement reflects its strategy to develop technologies to a certain maturity before finding a commercialization partner.
"We are delighted to have transferred FibroTrap to Debiopharm who will as of now continue with the development of FibroTrap technology, take it to market and realize its full potential in many different applications,” he added.
Debiopharm International is part of Debiopharm Group, a Swiss-based biopharmaceutical company, and Spinomix is a Swiss technology platform company providing sample processing to the life sciences sector.
Nasri Nahas, CEO, said: "Spinomix is very pleased to have this technology now under Debiopharm's solid product development expertise, allowing Spinomix to focus on commercializing its flagship sample processing technology MagPhase that we continue to validate in partnership with key players in research and industry."